Dihydroartemisinin 40 mg, piperaquine phosphate 320 mg
Treatment of uncomplicated malaria disease caused by P.falciparum and/or P.vivax malaria.
Day 1-3: ≥15 years, ≥60 kg 4 tab ≥15 years, 41-59 kg 3 tab 10-14 years, 31-40 kg 2 tab 5-9 years, 18-30 kg 1.5 tab 1-4 years, 11-17 kg 1 tab 2-11 months, 6-10 kg 0.5 tab 0-1 month, <5 kg 0.25 tab.
Hypersensitivity to dihydroartemisinin and piperaquine phosphate. Severe renal damage or liver disease. Blood disorders. Severe malaria according to WHO definition, drugs that prolong the QTc interval, symptomatic cardiac arrhythmias, severe hypertension, left ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac failure accompanied by reduced left ventricle ejection fraction, electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia. Pregnancy.
Hepatic and kidney function obstacle.
Nausea, vomiting, stomachache, diarrhea and loss of appetite. Dizziness, headache, insomnia; allergic reaction eg rash, pruritus. Transient decrease of peripheral erythrocyte, transient increase of SGPT, SGOT and blood creatinine. Laboratory exam abnormalities.
Drugs that prolong the QTc interval.
P01BF05 - artenimol and piperaquine ; Belongs to the class of artemisinin and derivatives, combinations. Used in the management of malaria.